Kura Oncology, Inc.
KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$9.07
Price+0.67%
$0.06
1Y
Price
Market Cap
$805.183m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-397.7%
EBITDA Margin-401.5%
Net Profit Margin-470.7%
Free Cash Flow Margin-397.7%
EBITDA Margin-401.5%
Net Profit Margin-470.7%
Free Cash Flow MarginRevenue
$71.639m
+6.2%
1y CAGR+10.5%
3y CAGR+7.9%
5y CAGREarnings
-$294.570m
-5.7%
1y CAGR-26.6%
3y CAGR-23.1%
5y CAGREPS
-$3.35
-5.3%
1y CAGR-20.0%
3y CAGR-15.6%
5y CAGRBook Value
$107.883m
$652.551m
Assets$544.668m
Liabilities$24.273m
DebtDebt to Assets
3.7%
-0.1x
Debt to EBITDAFree Cash Flow
-$84.459m
-19.5%
1y CAGR+11.6%
3y CAGR+5.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company